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Fig. 1 – AIDS-related cerebral toxoplasmosis cases and
deaths, São Paulo State, Brazil, 1982–2010.
Source: Base Integrada Paulista de AIDS (BIPAIDS) –
Cooperac¸ão Técnica PEDST/Aids-SP e Fundac¸ão SEADE,
MS/SVS/Departamento Nacional de DST, Aids e Hepatitesear Editor,
ighly active antiretroviral therapy (HAART) signiﬁcantly
educed the cerebral toxoplasmosis incidence in HIV-infected
atients from high-income countries.1 However, there is
carce epidemiological information about this neurological
pportunistic disease in low- and middle-income countries,
ncluding Brazil. In this letter, we would like to report some
ssues about AIDS-related cerebral toxoplasmosis in São Paulo
tate, Brazil. First, cerebral toxoplasmosis is the third ranking
IDS-deﬁning disease in the HAART-era,2 representing 10%
f admissions at Instituto de Infectologia Emilio Ribas (IIER) and
0% (n=3224) of reported cases among 2001–2005 to the Divi-
ion of Epidemiology Surveillance of the Centro de Referência
m Treinamento em DST/AIDS from São Paulo State.3 Second,
erebral toxoplasmosis led to the diagnosis of HIV infec-
ion in 35% of cases, and it deﬁned AIDS in 75% of cases
dmitted at IIER, suggesting a loss of diagnostic and ther-
peutic opportunities in a subset of HIV-infected persons
n Brazil, a middle-income country with universal and free
ccess to HAART.2 Third, short and long-term follow-up data
t IIER showed similar outcomes compared with AIDS-related
erebral toxoplasmosis from developed countries.1,2 How-
ver, cerebral toxoplasmosis remains a condition with poor
rognosis in the natural history of HIV-infected persons.1,4
ourth, cases reported to the Division of Epidemiology Surveil-
ance of the Centro de Referência em Treinamento em DST/AIDS
rom São Paulo State, showed a progressive decline of noti-
ed cases of AIDS-related cerebral toxoplasmosis during the
AART-era. Fig. 1 shows the evolution of the number of cases
rom 1982 to 2010 with 1825 reported cases in 1995 and
eclining to 392 cases in 2010. In addition, Fig. 1 shows a
onsistent declining of the number of reported AIDS-related
erebral toxoplasmosis deaths. Thus, there has been a reduc-
ion in the case-fatality rate of cerebral toxoplasmosis from
90% in the pre-HAART-era to ∼30% in recent years. In
ontrast to this data, the case-fatality rate at IIER (a ter-
iary referral center) was 13%, suggesting the heterogeneityVirais.
of outcomes among the several facilities.2 Fifth, similar to
that reported in the United States,4 toxoplasmosis cases
dropped markedly in the ﬁrst years of HAART in São Paulo
State, but decreased relatively little in recent years, con-
ﬁrming the persistence of late HIV diagnosis, non-adherence
to HAART and/or antiretroviral therapy failure in a subset
of HIV-infected patients. A number of strategies to reduce
morbidity and mortality among HIV-infected patients were
recently reviewed5 and several key principles can be pro-
posed to reduce AIDS-related cerebral toxoplasmosis: (1) early
HIV diagnosis; (2) linkage to and retention in care; (3) timely
treatment of HIV; (4) adherence to HAART; (5) primary and
secondary prophylaxis, and (6) optimized diagnosis and treat-
ment.
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Our data conﬁrm that frequency and case-fatality rates
of AIDS-related cerebral toxoplasmosis improved markedly
after the introduction of HAART. However, urgent implemen-
tation or optimization of both individual and public health
strategies is necessary to reduce current morbidity and mor-
tality. Although they are particularly vital to address in low
and middle-income countries, the challenges of AIDS-related
cerebral toxoplasmosis are global.1,4–6 A complete eradica-
tion of this parasitic disease is unlikely, but a comprehensive
approach to improve components of engagement in HIV will
determine the impact of this opportunistic disease in the
future.
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